Updated on 4 September 2014
The product is said to help the country cope with wounds associated with diabetes and flesh-eating diseases that are on a constant rise in China
Singapore: The Chinese drug regulatory body, the Food and Drug Administration has provided its approval for NovaBay's NeutroPhase skin and wound cleanser. The company said that it has received the nod to initiate sales of the product and that NovaBay's partner China Pioneer Pharma will be looking into that.
The product is said to help the country cope with wounds associated with diabetes and flesh-eating diseases that are on a constant rise in China.
The biopharmaceutical company further announced that the product will be sold throughout mainland China and that it would be shipping NeutroPhase to china in the fourth quarter of 2014 to support Pioneer's launch of the product in early 2015.
The company added in its announcement that chronic non-healing wounds, such as venous stasis ulcers, diabetic ulcers, and pressure ulcers are serious unmet medical needs that affect a patient's morbidity and mortality.
NeutroPhase is said to have shown remarkable properties in the management of these categories of wounds. Mr Paul Li (Mr Li Xinzhou), Chairman, Executive Director and Chief Executive Officer of Pioneer Pharma said in the statement, "The clearance of NeutroPhase in China will help Chinese doctors address major unmet medical needs. In China, we are experiencing a ‘catastrophic' epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, there are approximately 100 million Chinese already suffering from this condition and its chronic side effects such as diabetic ulcers and other chronic wounds-and their numbers are increasing."